Remaxol® in Mechanical Jaundice of Non-malignant Origin

PHASE3CompletedINTERVENTIONAL
Enrollment

342

Participants

Timeline

Start Date

April 3, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

April 13, 2020

Conditions
Jaundice, Obstructive
Interventions
DRUG

Remaxol (succinate + methionine + inosine + nicotinamide)

Solution for intravenous infusions, containing succinate, methionine, inosine, and nicotinamide in 400 ml glass bottle

DRUG

Ringer's Solution

Intravenous infusion, 400 or 800 ml

Trial Locations (13)

191015

North-West State Medical University named after I.I. Mechnikov, Saint Petersburg

196247

"State Budgetary Health Care Institution City Hospital № 26", Saint Petersburg

Unknown

Moscow 'City Clinical Hospital #24, Moscow

Moscow City Clinical Hospital #1 n.a.N.I.Pirogov, Moscow

Moscow City Clinical Hospital #29 n.a.N.A.Bauman, Moscow

Moscow City Clinical Hospital #67 n.a. L.A.Vorohobova, Moscow

Novosibirsk State Medical University, Novosibirsk

City Clinical Hospital of Emergency Care, Ryazan

Hospital for War Veterans, Saint Petersburg

Leningrad Regional Clinical Hospital, Saint Petersburg

Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine, Saint Petersburg

City Clinical Hospital #3 n.a.B.I.Alperovich, Tomsk

GBUZ YO 'Regional Clinical Hospital', Yaroslavl

All Listed Sponsors
lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT03418935 - Remaxol® in Mechanical Jaundice of Non-malignant Origin | Biotech Hunter | Biotech Hunter